Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV
In this open-label, randomized trial conducted in seven sub-Saharan African countries, patients for whom an initial HIV-1 treatment regimen had failed were switched to a second-line regimen of either dolutegravir or darunavir plus either tenofovir or zidovudine. Dolutegravir was noninferior to darun...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2021-07, Vol.385 (4), p.330-341 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 341 |
|---|---|
| container_issue | 4 |
| container_start_page | 330 |
| container_title | The New England journal of medicine |
| container_volume | 385 |
| creator | Paton, Nicholas I Musaazi, Joseph Kityo, Cissy Walimbwa, Stephen Hoppe, Anne Balyegisawa, Apolo Kaimal, Arvind Mirembe, Grace Tukamushabe, Phionah Ategeka, Gilbert Hakim, James Mugerwa, Henry Siika, Abraham Asienzo, Jesca Castelnuovo, Barbara Kiragga, Agnes Kambugu, Andrew |
| description | In this open-label, randomized trial conducted in seven sub-Saharan African countries, patients for whom an initial HIV-1 treatment regimen had failed were switched to a second-line regimen of either dolutegravir or darunavir plus either tenofovir or zidovudine. Dolutegravir was noninferior to darunavir and tenofovir was noninferior to zidovudine in their effects on viral suppression at 48 weeks. |
| doi_str_mv | 10.1056/NEJMoa2101609 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2554354546</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2554354546</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-4ff7361195c9fe035995be69e5ef63477f7d521949cd0a7603f16581f968e623</originalsourceid><addsrcrecordid>eNp10M9LwzAUB_AgipvTo1cpiOClmjQ_2hxlm24yFWR48FKy9kUz1mQm7cT_3s5NQcF3eTz48OXxReiY4AuCubi8H97eOZUQTASWO6hLOKUxY1jsoi7GSRazVNIOOghhjtshTO6jDmVJJpNUdNHjwC2aGl68WhkfOR8NlG_s12Fs1HfVzFhVG2ejd1O_Rs-mdKumNBbWdgrWabe2tYumHlQdjcZPh2hPq0WAo-3uoen1cNofxZOHm3H_ahIXVOI6ZlqnVBAieSE1YMql5DMQEjhoQVma6rTkCZFMFiVWqcBUE8EzoqXIQCS0h843sUvv3hoIdV6ZUMBioSy4JuQJ54xyxplo6ekfOneNt-1za0WzlhHaqnijCu9C8KDzpTeV8h85wfm66_xX160_2aY2swrKH_1dbgvONqCqQm5hXv0T9AneE4My</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2553835413</pqid></control><display><type>article</type><title>Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Paton, Nicholas I ; Musaazi, Joseph ; Kityo, Cissy ; Walimbwa, Stephen ; Hoppe, Anne ; Balyegisawa, Apolo ; Kaimal, Arvind ; Mirembe, Grace ; Tukamushabe, Phionah ; Ategeka, Gilbert ; Hakim, James ; Mugerwa, Henry ; Siika, Abraham ; Asienzo, Jesca ; Castelnuovo, Barbara ; Kiragga, Agnes ; Kambugu, Andrew</creator><creatorcontrib>Paton, Nicholas I ; Musaazi, Joseph ; Kityo, Cissy ; Walimbwa, Stephen ; Hoppe, Anne ; Balyegisawa, Apolo ; Kaimal, Arvind ; Mirembe, Grace ; Tukamushabe, Phionah ; Ategeka, Gilbert ; Hakim, James ; Mugerwa, Henry ; Siika, Abraham ; Asienzo, Jesca ; Castelnuovo, Barbara ; Kiragga, Agnes ; Kambugu, Andrew ; NADIA Trial Team</creatorcontrib><description>In this open-label, randomized trial conducted in seven sub-Saharan African countries, patients for whom an initial HIV-1 treatment regimen had failed were switched to a second-line regimen of either dolutegravir or darunavir plus either tenofovir or zidovudine. Dolutegravir was noninferior to darunavir and tenofovir was noninferior to zidovudine in their effects on viral suppression at 48 weeks.</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa2101609</identifier><identifier>PMID: 34289276</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject><![CDATA[Adolescent ; Adult ; Adverse events ; AIDS ; Anti-HIV Agents - administration & dosage ; Anti-HIV Agents - adverse effects ; Antiretroviral drugs ; Antiviral drugs ; Child ; Confidence intervals ; Darunavir - administration & dosage ; Darunavir - adverse effects ; Drug Resistance ; Drug Therapy, Combination ; Drugs ; Female ; Global Health ; Heterocyclic Compounds, 3-Ring - administration & dosage ; Heterocyclic Compounds, 3-Ring - adverse effects ; HIV ; HIV Infections - drug therapy ; HIV Infections - virology ; HIV-1 - isolation & purification ; Human immunodeficiency virus ; Humans ; Infectious Disease ; Lamivudine ; Male ; Middle Aged ; Oxazines - administration & dosage ; Oxazines - adverse effects ; Patients ; Piperazines - administration & dosage ; Piperazines - adverse effects ; Population ; Public health ; Pyridones - administration & dosage ; Pyridones - adverse effects ; Reverse Transcriptase Inhibitors - administration & dosage ; Reverse Transcriptase Inhibitors - adverse effects ; Ritonavir ; Statistical analysis ; Tenofovir ; Tenofovir - administration & dosage ; Tuberculosis ; Viral Load ; Young Adult ; Zidovudine ; Zidovudine - administration & dosage]]></subject><ispartof>The New England journal of medicine, 2021-07, Vol.385 (4), p.330-341</ispartof><rights>Copyright © 2021 Massachusetts Medical Society. All rights reserved.</rights><rights>Copyright © 2021 Massachusetts Medical Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-4ff7361195c9fe035995be69e5ef63477f7d521949cd0a7603f16581f968e623</citedby><cites>FETCH-LOGICAL-c390t-4ff7361195c9fe035995be69e5ef63477f7d521949cd0a7603f16581f968e623</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa2101609$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa2101609$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34289276$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Paton, Nicholas I</creatorcontrib><creatorcontrib>Musaazi, Joseph</creatorcontrib><creatorcontrib>Kityo, Cissy</creatorcontrib><creatorcontrib>Walimbwa, Stephen</creatorcontrib><creatorcontrib>Hoppe, Anne</creatorcontrib><creatorcontrib>Balyegisawa, Apolo</creatorcontrib><creatorcontrib>Kaimal, Arvind</creatorcontrib><creatorcontrib>Mirembe, Grace</creatorcontrib><creatorcontrib>Tukamushabe, Phionah</creatorcontrib><creatorcontrib>Ategeka, Gilbert</creatorcontrib><creatorcontrib>Hakim, James</creatorcontrib><creatorcontrib>Mugerwa, Henry</creatorcontrib><creatorcontrib>Siika, Abraham</creatorcontrib><creatorcontrib>Asienzo, Jesca</creatorcontrib><creatorcontrib>Castelnuovo, Barbara</creatorcontrib><creatorcontrib>Kiragga, Agnes</creatorcontrib><creatorcontrib>Kambugu, Andrew</creatorcontrib><creatorcontrib>NADIA Trial Team</creatorcontrib><title>Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>In this open-label, randomized trial conducted in seven sub-Saharan African countries, patients for whom an initial HIV-1 treatment regimen had failed were switched to a second-line regimen of either dolutegravir or darunavir plus either tenofovir or zidovudine. Dolutegravir was noninferior to darunavir and tenofovir was noninferior to zidovudine in their effects on viral suppression at 48 weeks.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Adverse events</subject><subject>AIDS</subject><subject>Anti-HIV Agents - administration & dosage</subject><subject>Anti-HIV Agents - adverse effects</subject><subject>Antiretroviral drugs</subject><subject>Antiviral drugs</subject><subject>Child</subject><subject>Confidence intervals</subject><subject>Darunavir - administration & dosage</subject><subject>Darunavir - adverse effects</subject><subject>Drug Resistance</subject><subject>Drug Therapy, Combination</subject><subject>Drugs</subject><subject>Female</subject><subject>Global Health</subject><subject>Heterocyclic Compounds, 3-Ring - administration & dosage</subject><subject>Heterocyclic Compounds, 3-Ring - adverse effects</subject><subject>HIV</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - virology</subject><subject>HIV-1 - isolation & purification</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Infectious Disease</subject><subject>Lamivudine</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Oxazines - administration & dosage</subject><subject>Oxazines - adverse effects</subject><subject>Patients</subject><subject>Piperazines - administration & dosage</subject><subject>Piperazines - adverse effects</subject><subject>Population</subject><subject>Public health</subject><subject>Pyridones - administration & dosage</subject><subject>Pyridones - adverse effects</subject><subject>Reverse Transcriptase Inhibitors - administration & dosage</subject><subject>Reverse Transcriptase Inhibitors - adverse effects</subject><subject>Ritonavir</subject><subject>Statistical analysis</subject><subject>Tenofovir</subject><subject>Tenofovir - administration & dosage</subject><subject>Tuberculosis</subject><subject>Viral Load</subject><subject>Young Adult</subject><subject>Zidovudine</subject><subject>Zidovudine - administration & dosage</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp10M9LwzAUB_AgipvTo1cpiOClmjQ_2hxlm24yFWR48FKy9kUz1mQm7cT_3s5NQcF3eTz48OXxReiY4AuCubi8H97eOZUQTASWO6hLOKUxY1jsoi7GSRazVNIOOghhjtshTO6jDmVJJpNUdNHjwC2aGl68WhkfOR8NlG_s12Fs1HfVzFhVG2ejd1O_Rs-mdKumNBbWdgrWabe2tYumHlQdjcZPh2hPq0WAo-3uoen1cNofxZOHm3H_ahIXVOI6ZlqnVBAieSE1YMql5DMQEjhoQVma6rTkCZFMFiVWqcBUE8EzoqXIQCS0h843sUvv3hoIdV6ZUMBioSy4JuQJ54xyxplo6ekfOneNt-1za0WzlhHaqnijCu9C8KDzpTeV8h85wfm66_xX160_2aY2swrKH_1dbgvONqCqQm5hXv0T9AneE4My</recordid><startdate>20210722</startdate><enddate>20210722</enddate><creator>Paton, Nicholas I</creator><creator>Musaazi, Joseph</creator><creator>Kityo, Cissy</creator><creator>Walimbwa, Stephen</creator><creator>Hoppe, Anne</creator><creator>Balyegisawa, Apolo</creator><creator>Kaimal, Arvind</creator><creator>Mirembe, Grace</creator><creator>Tukamushabe, Phionah</creator><creator>Ategeka, Gilbert</creator><creator>Hakim, James</creator><creator>Mugerwa, Henry</creator><creator>Siika, Abraham</creator><creator>Asienzo, Jesca</creator><creator>Castelnuovo, Barbara</creator><creator>Kiragga, Agnes</creator><creator>Kambugu, Andrew</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20210722</creationdate><title>Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV</title><author>Paton, Nicholas I ; Musaazi, Joseph ; Kityo, Cissy ; Walimbwa, Stephen ; Hoppe, Anne ; Balyegisawa, Apolo ; Kaimal, Arvind ; Mirembe, Grace ; Tukamushabe, Phionah ; Ategeka, Gilbert ; Hakim, James ; Mugerwa, Henry ; Siika, Abraham ; Asienzo, Jesca ; Castelnuovo, Barbara ; Kiragga, Agnes ; Kambugu, Andrew</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-4ff7361195c9fe035995be69e5ef63477f7d521949cd0a7603f16581f968e623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Adverse events</topic><topic>AIDS</topic><topic>Anti-HIV Agents - administration & dosage</topic><topic>Anti-HIV Agents - adverse effects</topic><topic>Antiretroviral drugs</topic><topic>Antiviral drugs</topic><topic>Child</topic><topic>Confidence intervals</topic><topic>Darunavir - administration & dosage</topic><topic>Darunavir - adverse effects</topic><topic>Drug Resistance</topic><topic>Drug Therapy, Combination</topic><topic>Drugs</topic><topic>Female</topic><topic>Global Health</topic><topic>Heterocyclic Compounds, 3-Ring - administration & dosage</topic><topic>Heterocyclic Compounds, 3-Ring - adverse effects</topic><topic>HIV</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - virology</topic><topic>HIV-1 - isolation & purification</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Infectious Disease</topic><topic>Lamivudine</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Oxazines - administration & dosage</topic><topic>Oxazines - adverse effects</topic><topic>Patients</topic><topic>Piperazines - administration & dosage</topic><topic>Piperazines - adverse effects</topic><topic>Population</topic><topic>Public health</topic><topic>Pyridones - administration & dosage</topic><topic>Pyridones - adverse effects</topic><topic>Reverse Transcriptase Inhibitors - administration & dosage</topic><topic>Reverse Transcriptase Inhibitors - adverse effects</topic><topic>Ritonavir</topic><topic>Statistical analysis</topic><topic>Tenofovir</topic><topic>Tenofovir - administration & dosage</topic><topic>Tuberculosis</topic><topic>Viral Load</topic><topic>Young Adult</topic><topic>Zidovudine</topic><topic>Zidovudine - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Paton, Nicholas I</creatorcontrib><creatorcontrib>Musaazi, Joseph</creatorcontrib><creatorcontrib>Kityo, Cissy</creatorcontrib><creatorcontrib>Walimbwa, Stephen</creatorcontrib><creatorcontrib>Hoppe, Anne</creatorcontrib><creatorcontrib>Balyegisawa, Apolo</creatorcontrib><creatorcontrib>Kaimal, Arvind</creatorcontrib><creatorcontrib>Mirembe, Grace</creatorcontrib><creatorcontrib>Tukamushabe, Phionah</creatorcontrib><creatorcontrib>Ategeka, Gilbert</creatorcontrib><creatorcontrib>Hakim, James</creatorcontrib><creatorcontrib>Mugerwa, Henry</creatorcontrib><creatorcontrib>Siika, Abraham</creatorcontrib><creatorcontrib>Asienzo, Jesca</creatorcontrib><creatorcontrib>Castelnuovo, Barbara</creatorcontrib><creatorcontrib>Kiragga, Agnes</creatorcontrib><creatorcontrib>Kambugu, Andrew</creatorcontrib><creatorcontrib>NADIA Trial Team</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Paton, Nicholas I</au><au>Musaazi, Joseph</au><au>Kityo, Cissy</au><au>Walimbwa, Stephen</au><au>Hoppe, Anne</au><au>Balyegisawa, Apolo</au><au>Kaimal, Arvind</au><au>Mirembe, Grace</au><au>Tukamushabe, Phionah</au><au>Ategeka, Gilbert</au><au>Hakim, James</au><au>Mugerwa, Henry</au><au>Siika, Abraham</au><au>Asienzo, Jesca</au><au>Castelnuovo, Barbara</au><au>Kiragga, Agnes</au><au>Kambugu, Andrew</au><aucorp>NADIA Trial Team</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2021-07-22</date><risdate>2021</risdate><volume>385</volume><issue>4</issue><spage>330</spage><epage>341</epage><pages>330-341</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>In this open-label, randomized trial conducted in seven sub-Saharan African countries, patients for whom an initial HIV-1 treatment regimen had failed were switched to a second-line regimen of either dolutegravir or darunavir plus either tenofovir or zidovudine. Dolutegravir was noninferior to darunavir and tenofovir was noninferior to zidovudine in their effects on viral suppression at 48 weeks.</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>34289276</pmid><doi>10.1056/NEJMoa2101609</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2021-07, Vol.385 (4), p.330-341 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2554354546 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Adolescent Adult Adverse events AIDS Anti-HIV Agents - administration & dosage Anti-HIV Agents - adverse effects Antiretroviral drugs Antiviral drugs Child Confidence intervals Darunavir - administration & dosage Darunavir - adverse effects Drug Resistance Drug Therapy, Combination Drugs Female Global Health Heterocyclic Compounds, 3-Ring - administration & dosage Heterocyclic Compounds, 3-Ring - adverse effects HIV HIV Infections - drug therapy HIV Infections - virology HIV-1 - isolation & purification Human immunodeficiency virus Humans Infectious Disease Lamivudine Male Middle Aged Oxazines - administration & dosage Oxazines - adverse effects Patients Piperazines - administration & dosage Piperazines - adverse effects Population Public health Pyridones - administration & dosage Pyridones - adverse effects Reverse Transcriptase Inhibitors - administration & dosage Reverse Transcriptase Inhibitors - adverse effects Ritonavir Statistical analysis Tenofovir Tenofovir - administration & dosage Tuberculosis Viral Load Young Adult Zidovudine Zidovudine - administration & dosage |
| title | Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T16%3A35%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dolutegravir%20or%20Darunavir%20in%20Combination%20with%20Zidovudine%20or%20Tenofovir%20to%20Treat%20HIV&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Paton,%20Nicholas%20I&rft.aucorp=NADIA%20Trial%20Team&rft.date=2021-07-22&rft.volume=385&rft.issue=4&rft.spage=330&rft.epage=341&rft.pages=330-341&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMoa2101609&rft_dat=%3Cproquest_cross%3E2554354546%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2553835413&rft_id=info:pmid/34289276&rfr_iscdi=true |